<p>Amneal Pharmaceuticals Inc. has received U.S. Food and Drug Administration (FDA) approval for its epinephrine injection USP, 1 mg/mL, available in both single-dose and multi-dose vials. This critical emergency medicine is utilized in hospitals, emergency departments, and other acute care facilities for the treatment of allergic reactions, including anaphylaxis, and to manage hypotension associated with septic shock. The approval expands Amneal’s injectables portfolio, reinforcing the company’s commitment to supplying essential medicines to the U.S. healthcare system. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9599363) on December 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

AMRX

<p>Amneal Pharmaceuticals Inc. has received FDA approval for its epinephrine injection, expanding its injectables portfolio. This medicine is used in hospitals for allergic reactions and septic shock. The approval highlights Amneal's commitment to providing essential medicines to the U.S. healthcare system.</p>

FDA Approves Amneal Epinephrine Injection for U.S. Hospitals